• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

The importance of extended working hours for work-related injuries
Discussion of Reduction Strategies and Behavioral Responses from a North American Perspective. Euro J Trans Infra Res. 2002;2(4). 21. POPM.gov [internet] Policy, Data, Oversight. Available from: https://www.opm.gov/policy-data-oversight/pay-leave/work-sched ules/fact-sheets/alternative-work-schedules-compressed-work-schedules/. Accessed June 30, 2021. 22. Kivimäki M, Nyberg ST, Batty GD, Fransson EI, Heikkilä K, Alfredsson L, et al. Job strain as a risk factor for coronary heart disease: a collaborative meta-analysis of individual participant data. Lancet. 2012;380(9852):1491-7. https://doi.org/10.1016/S0140-6736(12)60...
Source: Scandinavian Journal of Work, Environment and Health - August 11, 2021 Category: Occupational Health Tags: Editorial Source Type: research

Associations between Greenness, Impervious Surface Area, and Nighttime Lights on Biomarkers of Vascular Aging in Chennai, India
Conclusion: Greenness, ISA, and NTL were associated with increased SBP, DBP, and cPP, and with reduced FMD, suggesting a possible additional EVA pathway for the relationship between urbanization and increased CVD prevalence in urban India. https://doi.org/10.1289/EHP541 Received: 20 May 2016 Revised: 03 January 2017 Accepted: 23 January 2017 Published: 02 August 2017 Address correspondence to K.J. Lane, Yale School of Forestry and Environmental Studies, 195 Prospect Street, New Haven, CT 06511 USA. Telephone: (781) 696-4537; Email: kevin.lane@yale.edu Supplemental Material is available online (https://doi.org/10.1289...
Source: EHP Research - August 2, 2017 Category: Environmental Health Authors: Daniil Lyalko Tags: Research Source Type: research

Janssen Announces U.S. FDA Approval of INVEGA HAFYERA ™(6-month paliperidone palmitate), First and Only Twice-Yearly Treatment for Adults with Schizophrenia
TITUSVILLE, N.J., Sept. 1, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the U.S. Food and Drug Administration (FDA) has approved long-acting atypical antipsychotic INVEGA HAFYERA™ (6-month paliperidone palmitate), the first-and-only twice-yearly injectable for the treatment of schizophrenia in adults. Before transitioning to INVEGA HAFYERA™, patients must be adequately treated with INVEGA SUSTENNA® (1-month paliperidone palmitate) for at least four months, or INVEGA TRINZA® (3-month paliperidone palmitate) for at least one 3-month injection cycle.1 The FDA approval of INVEGA ...
Source: Johnson and Johnson - September 1, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news